Some case experiences have been printed suggesting affiliation of celiac illness (CD) with tuberculosis (TB) and with deep vein thrombosis (DVT) however principally in grownup populations and in several sufferers. We report a 13-year-old woman just lately recognized with CD introduced to pediatric emergency at a tertiary instructing hospital in north India with complaints of generalized weak spot, ache and swelling over left decrease limb that subsequently was recognized to have disseminated TB and left decrease limb DVT. She was handled with course of anti-tubercular medicine, short-term anticoagulant remedy, and gluten free eating regimen with constructive outcomes over subsequent three months.
To one of the best of authors’ information, no earlier experiences have but recommended a coexistence of disseminated TB and peripheral deep vein thrombosis and CD in a single single pediatric affected person. Methimazole (MMI) is used to deal with hyperthyroidism in Graves’ illness. It’s uncommon to come across sufferers in whom hyperthyroidism can’t be managed utilizing excessive doses of MMI.Case presentation: A 21-year-old girl was referred to our hospital due to MMI-resistant Graves’ illness. Though her MMI dose had been elevated to 120 mg/day, her serum thyroid hormone focus was too excessive to be measured.
Further remedy with lithium carbonate, after which with dexamethasone and inorganic iodine, was initiated. After 14 days, the affected person’s serum thyroid hormone focus normalized, whereas she was taking 150 mg/day MMI, 800 mg/day lithium carbonate, 6 mg/day dexamethasone and 306 mg/day inorganic iodine, and whole thyroidectomy was then carried out. The affected person was discharged eight days after the thyroidectomy and skilled no main issues. Now we have introduced a uncommon case of Graves’ illness that was proof against high-dose MMI. Mixture remedy of MMI with lithium carbonate, dexamethasone and inorganic iodine might characterize a therapeutic possibility for the preoperative preparation of sufferers with MMI-resistant Graves’ illness.
A thematic research: impression of COVID-19 pandemic on uncommon illness organisations and sufferers throughout ten jurisdictions within the Asia Pacific area
This research assesses the areas and extent of impression of the Coronavirus Illness of 2019 (COVID-19) pandemic on uncommon illness (RD) organisations within the Asia Pacific area. There isn’t a current literature that focuses on such impression on RD organisations in any jurisdictions, nor RD populations throughout a number of jurisdictions within the Asia Pacific area. A cross-sectional survey was distributed to RD organisations between April and Might 2020. Quantitative and qualitative knowledge on the impression of COVID-19 on RD organisations and sufferers have been collected from the organisation consultant’s perspective. Qualitative knowledge was analysed utilizing thematic evaluation.
A complete of 80 RD organisations from Australia, Hong Kong Particular Administrative Area of China, India, Japan, mainland China, Malaysia, New Zealand, the Philippines, Singapore and Taiwan participated within the research. Of all, 89% have been involved concerning the impression of pandemic on their organisations. Outcomes point out that 63% of the organisations functioned at a lowered capability and 42% acknowledged a lower in funding as their largest problem. Total, 95% believed their sufferers have been impacted, significantly in healthcare entry, social lives, bodily well being, psychological well being and monetary impression. Particularly, 43% recognized the lowered healthcare entry as their high impression, adopted by 26% concerning the impression on each day residing and social life. Focus group assembly mentioned differential impression throughout jurisdictions and level in the direction of telemedicine and digitalisation as potential options.
This serves as the primary research to evaluate the impression of COVID-19 on RD sufferers and organisations throughout a number of jurisdictions within the Asia Pacific area, figuring out main themes on the impression on each RD sufferers and organisations. By together with 80 organisations from ten jurisdictions, our research presents essentially the most complete evaluation of the pandemic’s impression so far. It highlights the necessity for psychological well being assist and sheds gentle on transferring in the direction of telemedicine and digitalisation of organisation operation, which constitutes a sustainable mannequin in instances of pandemics and past.
Perception into the genetic etiology of Alzheimer’s illness: A complete evaluate of the position of uncommon variants
Early-onset Alzheimer’s illness (EOAD) is generally called a dominant illness resulting from extremely penetrant pathogenic mutations within the amyloid precursor protein, presenilin 1 and a couple of. Nonetheless, they clarify solely a fraction of EOAD sufferers (5% to 10%). Moreover, solely 10% to 15% of EOAD households current with clear autosomal dominant inheritance. Research confirmed that solely 35% to 60% of EOAD sufferers have at the very least one affected first-degree relative. Mother or father-offspring concordance in EOAD was estimated to be <10%, indicating that full penetrant dominant alleles usually are not the only real gamers in EOAD.
We intention to summarize present information of uncommon variants underlying familial and seemingly sporadic Alzheimer’s illness (AD) sufferers. Genetic findings point out that along with the amyloid beta pathway, different pathways are of significance in AD pathophysiology. We talk about the difficulties in decoding the affect of uncommon variants on illness onset and we underline the worth of rigorously chosen ethnicity-matched cohorts in AD genetic analysis. A follow-up focus group assembly was carried out in August 2020 to validate the survey findings and to debate particular wants, assist and suggestions for sustainable healthcare techniques in the course of the pandemic.
 ELISA Kit) Bovine Immunoglobulin A (IgA) ELISA Kit |
|
RD-IgA-b-48Tests |
Reddot Biotech |
48 Tests |
EUR 555 |
Bovine Immunoglobulin A (IgA) ELISA Kit |
|
RD-IgA-b-96Tests |
Reddot Biotech |
96 Tests |
EUR 771 |
 ELISA Kit) Mouse Immunoglobulin A (IgA) ELISA Kit |
|
RD-IgA-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 489 |
Mouse Immunoglobulin A (IgA) ELISA Kit |
|
RD-IgA-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 677 |
 ELISA Kit) Porcine Immunoglobulin A (IgA) ELISA Kit |
|
RD-IgA-p-48Tests |
Reddot Biotech |
48 Tests |
EUR 555 |
Porcine Immunoglobulin A (IgA) ELISA Kit |
|
RD-IgA-p-96Tests |
Reddot Biotech |
96 Tests |
EUR 771 |
 ELISA Kit) Rat Immunoglobulin A (IgA) ELISA Kit |
|
RD-IgA-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 511 |
Rat Immunoglobulin A (IgA) ELISA Kit |
|
RD-IgA-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 709 |
Bovine Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-b-48T |
DL Develop |
48T |
EUR 547 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Immunoglobulin A (IgA) in samples from serum, plasma, saliva or other biological fluids. |
Bovine Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-b-96T |
DL Develop |
96T |
EUR 715 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Immunoglobulin A (IgA) in samples from serum, plasma, saliva or other biological fluids. |
 ELISA Kit) Chicken Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-Ch-48T |
DL Develop |
48T |
EUR 508 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Chicken Immunoglobulin A (IgA) in samples from serum, plasma or other biological fluids. |
Chicken Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-Ch-96T |
DL Develop |
96T |
EUR 661 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Chicken Immunoglobulin A (IgA) in samples from serum, plasma or other biological fluids. |
 ELISA Kit) Human Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-Hu-48T |
DL Develop |
48T |
EUR 441 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Immunoglobulin A (IgA) in samples from serum, plasma, saliva or other biological fluids. |
Human Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-Hu-96T |
DL Develop |
96T |
EUR 570 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Immunoglobulin A (IgA) in samples from serum, plasma, saliva or other biological fluids. |
Mouse Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-Mu-48T |
DL Develop |
48T |
EUR 489 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Immunoglobulin A (IgA) in samples from serum, plasma or other biological fluids. |
Mouse Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-Mu-96T |
DL Develop |
96T |
EUR 635 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Immunoglobulin A (IgA) in samples from serum, plasma or other biological fluids. |
Porcine Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-p-48T |
DL Develop |
48T |
EUR 547 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Immunoglobulin A (IgA) in samples from serum, plasma or other biological fluids. |
Porcine Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-p-96T |
DL Develop |
96T |
EUR 715 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Immunoglobulin A (IgA) in samples from serum, plasma or other biological fluids. |
Rat Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-Ra-48T |
DL Develop |
48T |
EUR 508 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Immunoglobulin A (IgA) in samples from serum, plasma or other biological fluids. |
Rat Immunoglobulin A (IgA) ELISA Kit |
|
DLR-IgA-Ra-96T |
DL Develop |
96T |
EUR 661 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Immunoglobulin A (IgA) in samples from serum, plasma or other biological fluids. |
Bovine Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-b-48Tests |
Reddot Biotech |
48 Tests |
EUR 580 |
Bovine Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-b-96Tests |
Reddot Biotech |
96 Tests |
EUR 807 |
Chicken Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-Ch-48Tests |
Reddot Biotech |
48 Tests |
EUR 534 |
Chicken Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-Ch-96Tests |
Reddot Biotech |
96 Tests |
EUR 742 |
Human Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 455 |
Human Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 629 |
Mouse Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 511 |
Mouse Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 709 |
Porcine Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-p-48Tests |
Reddot Biotech |
48 Tests |
EUR 580 |
Porcine Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-p-96Tests |
Reddot Biotech |
96 Tests |
EUR 807 |
Rat Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 534 |
Rat Immunoglobulin A (IgA) ELISA Kit |
|
RDR-IgA-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 742 |
 IgA ELISA kit, 96 tests, quantitative) Rat Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgA ELISA kit, 96 tests, quantitative |
|
4270-30-IGA |
Alpha Diagnostics |
1 Kit |
EUR 895 |
 IgA ELISA kit, 96 tests, quantitative) Human Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgA ELISA kit, 96 tests, quantitative |
|
4200-30-IGA |
Alpha Diagnostics |
1 Kit |
EUR 895 |
 IgA ELISA kit, 96 tests, quantitative) Mouse Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgA ELISA kit, 96 tests, quantitative |
|
4210-30-IGA |
Alpha Diagnostics |
1 Kit |
EUR 895 |
 IgA ELISA kit, 96 tests, quantitative) Monkey Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgA ELISA kit, 96 tests, quantitative |
|
4250-30-IGA |
Alpha Diagnostics |
1 Kit |
EUR 1017 |
 NS1 protein IgA ELISA kit, 96 tests, Quantitative) Recombivirus? Human Anti-Zika Virus (ZIKV) NS1 protein IgA ELISA kit, 96 tests, Quantitative |
|
RV-403300-IgA |
Alpha Diagnostics |
1 Kit |
EUR 1138 |
/rotavirus IgA ELISA Kit, 2x96 tests) RecombiVirus Rat Epizootic diarrhea of infant mice (EDIM)/rotavirus IgA ELISA Kit, 2x96 tests |
|
AE-300415-IgA |
Alpha Diagnostics |
1 Kit |
EUR 1260 |
 ELISA Kit, 96 tests, Quantitative) Mouse Anti-Meningococcal A/C/W/Y Oligosaccharides IgA (Combo) ELISA Kit, 96 tests, Quantitative |
|
600-888-IGA |
Alpha Diagnostics |
1 Kit |
EUR 1017 |
 ELISA Kit, 96 tests, Quantitative) Human Anti-Meningococcal Group A/C/W/Y Oligosaccharides IgA (Combo) ELISA Kit, 96 tests, Quantitative |
|
600-883-IGA |
Alpha Diagnostics |
1 Kit |
EUR 1017 |
 Feline Infectious peritonitis protein |
|
30-1257 |
Fitzgerald |
1 mg |
EUR 457 |
|
Description: Purified native Feline Infectious peritonitis protein |
 Toxoplasma Gondii Antibody |
|
abx022275-1mg |
Abbexa |
1 mg |
EUR 704 |
|
|
Toxoplasma Gondii Antibody |
|
abx022276-1mg |
Abbexa |
1 mg |
EUR 1414 |
|
|
Toxoplasma Gondii Antibody |
|
abx022278-1mg |
Abbexa |
1 mg |
EUR 1052 |
|
|
Toxoplasma Gondii Antibody |
|
abx022279-1mg |
Abbexa |
1 mg |
EUR 1094 |
|
|
Toxoplasma Gondii Antibody |
|
abx023190-1ml |
Abbexa |
1 ml |
EUR 648 |
|
|
 Toxoplasma Antigen Protein |
|
abx169702-100mg |
Abbexa |
100 mg |
EUR 1135 |
|
|
 Toxoplasma gondii antibody |
|
20-TG19 |
Fitzgerald |
1 mg |
EUR 116 |
|
Description: Goat polyclonal Toxoplasma gondii antibody |
Toxoplasma gondii antibody |
|
20-TR19 |
Fitzgerald |
1 mg |
EUR 314 |
|
Description: Rabbit polyclonal Toxoplasma gondii antibody |
Toxoplasma gondii antibody |
|
20C-CR1241RP |
Fitzgerald |
1 ml |
EUR 458 |
|
Description: Rabbit polyclonal Toxoplasma gondii antibody |
Toxoplasma gondii antibody |
|
10-T19A |
Fitzgerald |
200 ug |
EUR 247 |
|
Description: Mouse monoclonal Toxoplasma gondii antibody |
Toxoplasma gondii antibody |
|
10-T19B |
Fitzgerald |
200 ug |
EUR 726 |
|
Description: Mouse monoclonal Toxoplasma gondii antibody |
Toxoplasma gondii antibody |
|
10C-CR1241M1 |
Fitzgerald |
100 ug |
EUR 348 |
|
Description: Mouse monoclonal Toxoplasma gondii antibody |
Toxoplasma gondii antibody |
|
10C-CR1241M2 |
Fitzgerald |
100 ug |
EUR 392 |
|
Description: Mouse monoclonal Toxoplasma gondii antibody |
 Toxoplasma gondii protein |
|
30-1312 |
Fitzgerald |
1 ml |
EUR 295 |
|
Description: Purified native Toxoplasma gondii protein |
Toxoplasma gondii protein |
|
30-1316 |
Fitzgerald |
1 ml |
EUR 295 |
|
Description: Purified native Toxoplasma gondii protein |
Toxoplasma gondii protein |
|
30-1317 |
Fitzgerald |
1 ml |
EUR 295 |
|
Description: Purified Toxoplasma Gondii Tachyzoite |
Toxoplasma gondii protein |
|
30-AT54 |
Fitzgerald |
1 ml |
EUR 349 |
|
Description: Purified native Toxoplasma gondii protein |
Toxoplasma gondii protein |
|
30-AT56 |
Fitzgerald |
1 ml |
EUR 530 |
|
Description: Purified native Toxoplasma gondii protein (Level 2) |
Toxoplasma gondii protein |
|
30-AT57 |
Fitzgerald |
1 ml |
EUR 817 |
|
Description: Purified native Toxoplasma gondii protein |
) Common diseases of soft tissue, 24 cases (2.5mm) |
|
SFD241 |
Pantomics |
1 |
EUR 190 |
|
Description: Soft tissue disease tissue array, 24 cases of normal, reactive and tumor conditions of various soft tissues |
) Common diseases of soft tissue, 24 cases (2mm) |
|
SFD481 |
Pantomics |
1 |
EUR 221 |
|
Description: Soft tissue disease tissue array, 24 cases of reactive and tumor conditions of various soft tissues in duplicates. |
) Common diseases of the skin, 24 cases (2.5mm) |
|
SKD241 |
Pantomics |
1 |
EUR 190 |
|
Description: Skin disease tissue array, 24 cases of normal, reactive and tumor tissues of the skin |
) Common diseases of the skin, 24 cases (2mm) |
|
SKD481 |
Pantomics |
1 |
EUR 221 |
|
Description: Skin disease tissue array, 24 cases of reactive and tumor conditions of the skin in duplicates. |
) Common diseases of the lung, 15 cases (2.5mm) |
|
LUD151 |
Pantomics |
1 |
EUR 190 |
|
Description: Lung disease tissue array, 7 types, 15 cases of normal, inflammatory and tumor tissues of the lung. |
) Common diseases of the lung, 24 cases (2mm) |
|
LUD481 |
Pantomics |
1 |
EUR 250 |
|
Description: Lung disease tissue array, non-overlapping with LUD151, 24 cases of normal, chronic bronchitis, emphysema, TB and tumor tissues of the lung in duplicates. |
) Common diseases of the liver, 24 cases (2mm) |
|
LVD481 |
Pantomics |
1 |
EUR 250 |
|
Description: Liver common disease tissue array, 24 cases of normal, hepatitis, viral related cirrhosis and tumor tissues of the liver in duplicates. |
) Common diseases of the prostate, 48 cases (1.5mm) |
|
PRD961 |
Pantomics |
1 |
EUR 295 |
|
Description: Prostate disease tissue array, 48 cases of normal, hyperplastic and neoplastic prostate tissues in duplicates. |
) Common diseases of the stomach, 24 cases (2mm) |
|
STD481 |
Pantomics |
1 |
EUR 221 |
|
Description: Stomach disease tissue array, 48 cores, 24 cases of normal, inflammatory and neoplastic conditions of the stomach in duplicates |
) Common diseases of the thyroid, 18 cases (2.5mm) |
|
THD181 |
Pantomics |
1 |
EUR 161 |
|
Description: Thyroid disease tissue array, 6 types, 18 cases of normal, inflammatory and neoplastic conditions of the thyroid |
) Common diseases of the thyroid, 48 cases (1.5mm) |
|
THD961 |
Pantomics |
1 |
EUR 250 |
|
Description: Thyroid disease tissue array, 96 cores, 48 cases of normal, inflammatory and neoplastic conditions of the thyroid in duplicates |
) Common diseases of the breast, 102 cases (1.5mm) |
|
BRD1021 |
Pantomics |
1 |
EUR 250 |
|
Description: Breast disease tissue array containing 102 cases of normal breasts, fibrocystic changes, proliferative breast diseases (atypical) and various types and stages of breast cancers with AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
) Common diseases of the breast, 18 cases (2.5mm) |
|
BRD181 |
Pantomics |
1 |
EUR 129 |
|
Description: Breast disease tissue array containing 18 cases of normal, hyperplasia and neoplastic breast tissues with AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
) Common diseases of the breast, 24 cases (2mm) |
|
BRD481 |
Pantomics |
1 |
EUR 220 |
|
Description: Breast disease tissue array containing 24 cases of normal, hyperplasia and neoplastic breast tissues with AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
) Common diseases of the breast, 48 cases (2mm) |
|
BRD961 |
Pantomics |
1 |
EUR 250 |
|
Description: Breast disease tissue array containing 48 cases of normal, hyperplasia and neoplastic breast tissues in duplicates with AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
 Recombinant Toxoplasma Gondii Toxoplasma P22 Protein, His, E.coli-100ug |
|
QP13787-100ug |
EnQuireBio |
100ug |
EUR 218 |
 Recombinant Toxoplasma Gondii Toxoplasma P22 Protein, His, E.coli-1mg |
|
QP13787-1mg |
EnQuireBio |
1mg |
EUR 1261 |
 Recombinant Toxoplasma Gondii Toxoplasma P22 Protein, His, E.coli-500ug |
|
QP13787-500ug |
EnQuireBio |
500ug |
EUR 663 |
 Recombinant Toxoplasma Gondii Toxoplasma P32 Protein, His, E.coli-100ug |
|
QP13788-100ug |
EnQuireBio |
100ug |
EUR 218 |
 Recombinant Toxoplasma Gondii Toxoplasma P32 Protein, His, E.coli-1mg |
|
QP13788-1mg |
EnQuireBio |
1mg |
EUR 1261 |
 Recombinant Toxoplasma Gondii Toxoplasma P32 Protein, His, E.coli-500ug |
|
QP13788-500ug |
EnQuireBio |
500ug |
EUR 663 |
 Infectious Laryngotracheitis virus PCR kit |
|
PCR-V009-48D |
Bioingentech |
50T |
EUR 453 |
Infectious Laryngotracheitis virus PCR kit |
|
PCR-V009-96D |
Bioingentech |
100T |
EUR 572 |
 Chicken Infectious Coryza ELISA Kit |
|
abx052624-96tests |
Abbexa |
96 tests |
EUR 668 |
|
|
 IgA ELISA Kit; (23 serotypes: 1, 2, 3, 4, 5, 6b, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F), 96 tests, quantitative) Mouse Anti-S. Pneumococcal vaccine (Pneumovax/CPS23) IgA ELISA Kit; (23 serotypes: 1, 2, 3, 4, 5, 6b, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F), 96 tests, quantitative |
|
560-186-IGA |
Alpha Diagnostics |
1 Kit |
EUR 1078 |
 IgA ELISA Kit; (23 serotypes: 1, 2, 3, 4, 5, 6b, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F), 96 tests, quantitative) Human Anti-S. Pneumococcal vaccine (Pneumovax/CPS23) IgA ELISA Kit; (23 serotypes: 1, 2, 3, 4, 5, 6b, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F), 96 tests, quantitative |
|
560-196-IGA |
Alpha Diagnostics |
1 Kit |
EUR 1078 |
) Toxoplasma gondii Profilin (PRF) |
|
1-CSB-RP151074Ba |
Cusabio |
-
EUR 611.00
-
EUR 309.00
-
EUR 1827.00
-
EUR 939.00
-
EUR 1218.00
-
EUR 397.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Toxoplasma gondii Profilin(PRF) expressed in E.coli |
Toxoplasma gondii Profilin (PRF) |
|
1-CSB-YP151074Ba |
Cusabio |
-
EUR 679.00
-
EUR 335.00
-
EUR 2172.00
-
EUR 1051.00
-
EUR 1442.00
-
EUR 435.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Toxoplasma gondii Profilin(PRF) expressed in Yeast |
 Toxoplasma gondii PCR kit |
|
PCR-VH092-48D |
Bioingentech |
50T |
EUR 453 |
Toxoplasma gondii PCR kit |
|
PCR-VH092-96D |
Bioingentech |
100T |
EUR 572 |
 Toxoplasma IgG ELISA Kit |
|
DEIA379 |
Creative Diagnostics |
96T |
EUR 562 |
|
Description: The Toxoplasma IgG Antibody ELISA Test Kit has been designed for the detection and the quantitative determination of specific IgG antibodies against Toxoplasma in serum and plasma. |
 Toxoplasma IgM ELISA Kit |
|
DEIA380 |
Creative Diagnostics |
96T |
EUR 562 |
|
Description: The Toxoplasma IgM Antibody ELISA Test Kit has been designed for the detection and the quantitative determination of specific IgM antibodies against Toxoplasma gondii in serum and plasma. |
 Toxoplasma Gondii MIC 3 |
|
PR27132 |
Neuromics |
500 ug |
EUR 833 |
 Toxoplasma gondii MIC3 Protein |
|
abx060661-1mg |
Abbexa |
1 mg |
EUR 1344 |
|
|
 Toxoplasma gondii antigen Protein |
|
abx061385-1ml |
Abbexa |
1 ml |
EUR 648 |
|
|
 Recombinant Toxoplasma Gondii MIC3 |
|
7-07537 |
CHI Scientific |
100µg |
Ask for price |
Recombinant Toxoplasma Gondii MIC3 |
|
7-07538 |
CHI Scientific |
500µg |
Ask for price |
Recombinant Toxoplasma Gondii MIC3 |
|
7-07539 |
CHI Scientific |
1000µg |
Ask for price |
) Toxoplasma Gondii Antibody (HRP) |
|
abx022273-1mg |
Abbexa |
1 mg |
EUR 1135 |
|
|
 Toxoplasma gondii MIC3 Antibody |
|
abx022280-1mg |
Abbexa |
1 mg |
EUR 1066 |
|
|
A retrospective case research was carried out. A number of data sources have been used to: decide the standing of eculizumab patents; study the designation of orphan drug standing by US, European, Japanese, and Brazilian regulatory authorities to find out registration standing and permitted medical indications; estimate the prevalence of related medical circumstances; examine the historical past of the drug producer, Alexion Prescription drugs, Inc., and its financialized enterprise mannequin; and study international eculizumab gross sales revenues since its first advertising and marketing authorization.
